Safety Evaluation of Large-Scale Administration of a Novel Human Diploid (SV-1) Cell Line-Derived Varicella Attenuated Live Vaccine in Children 7-12 Years Old.

ABSTRACT: Objectives: Varicella is a highly contagious viral disease affecting children. The SV-1 cell line-based varicella attenuated live vaccine (SV-1VarV) is the first vaccine produced using the human diploid SV-1 cell substrate. This study evaluated the real-world safety of SV-1VarV among school-aged children in Jiangsu Province, China. Methods: A retrospective descriptive study was conducted using data from the Jiangsu Provincial Immunization Program Information System and the Chinese National Adverse Event Following Immunization Information System (CNAEFIS). Children aged 7-12 years who received SV-1VarV between July 2024 and March 2025 were included. The incidence, clinical characteristics, and demographic patterns of Adverse Events Following Immunization (AEFI) were analyzed.

SUBMITTER: Zhu Y 

PROVIDER: S-EPMC12846628 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature